<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-76197</identifier>
<setSpec>1132-8460</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Evolution of women with osteoporosis treated for more than three years</dc:title>
<dc:description xml:lang="en">We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p &lt; 0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%). The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable. We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors(AU)</dc:description>
<dc:creator>Olmo Fernández-Delgado, J. a</dc:creator>
<dc:creator>Canteras Jordana, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Presentamos la evolución de 41 pacientes con osteoporosis posmenopáusica que han seguido tratamiento durante más de tres años (86 meses de media). Treinta y cinco pacientes (85%) presentaron incrementos de la densidad mineral ósea (DMO) en columna, con una ganancia media del 21%, siendo los cambios estadísticamente significativos (p &lt; 0,005); el 63% mostró incrementos en cadera, pero no fueron significativos. Trece pacientes presentaron alguna fractura por fragilidad y 6 de ellas sufrieron más de un evento. Por orden de frecuencia fueron 8 fracturas vertebrales (19,5%), 5 de la extremidad distal de radio (12%), 3 de húmero (7,5%) y 2 de cadera (5%). El tratamiento más utilizado fue alendronato (71%), seguido de raloxifeno (58%) y risedronato (54%). Utilizando el test de Morisky, el 48% de las pacientes era buena cumplidora. Hemos encontrado correlación entre los aumentos de la DMO y la aparición de fractura, pero no con otros factores de riesgo analizados(AU)</dc:description>
<dc:source>Rev. esp. enferm. metab. óseas (Ed. impr.);18(3): 45-50, jul.-sept. 2009. tab, ilus</dc:source>
<dc:identifier>ibc-76197</dc:identifier>
<dc:title xml:lang="es">Evolución de mujeres con osteoporosis tratadas durante más de tres años</dc:title>
<dc:subject>^d24823^s22016</dc:subject>
<dc:subject>^d34394^s22073</dc:subject>
<dc:subject>^d24823^s22057</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d32988^s22073</dc:subject>
<dc:subject>^d24823^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d10192^s22080</dc:subject>
<dc:subject>^d24823^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d10192^s22054</dc:subject>
<dc:subject>^d10192^s22032</dc:subject>
<dc:subject>^d10192^s22012</dc:subject>
<dc:subject>^d24543^s22021</dc:subject>
<dc:subject>^d24543^s22031</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d10192^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200909</dc:date>
</metadata>
</record>
</ibecs-document>
